Therapeutic Effects of Topical Herbal Medicine -Rhubarb Ointment on Rosacea

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05045469
Collaborator
(none)
24
1
2
24
1

Study Details

Study Description

Brief Summary

The aim of this study is to investigate the effects of topical herbal medicine in the patients with rosacea.

Condition or Disease Intervention/Treatment Phase
  • Drug: dian dao san
Phase 2

Detailed Description

Rosacea is a chronic inflammatory disorder which affects the cheek, nose, chin, forehead and eyes. It is typically characterized by cutaneous signs such as flushing, erythema, telangiectasia, papules, and pustules in the face. The pathogenic mechanism of rosacea is unknown, and there is no cure for rosacea. The therapeutic approaches include oral medicine, topical medicine and surgical interventions depending on the different subtypes of rosacea. The recent study demonstrates that combination therapy may be more effectively improved the symptoms of rosacea. Dian dao san is a topical herbal compound for reducing the features as flushing, erythema, papules, and pustules for years. The investigators hypothesize that dian dao san can be more beneficial in treating the patients with rosacea and improving the quality of life.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Therapeutic Effects of Topical Herbal Medicine on Rosacea
Actual Study Start Date :
Aug 4, 2021
Anticipated Primary Completion Date :
Aug 4, 2022
Anticipated Study Completion Date :
Aug 4, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: group A (dian dao san group)

Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.

Drug: dian dao san
dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks

Placebo Comparator: group B( topical medicine without therapeutic effects)

Placebo (topical medicine without therapeutic effects) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.

Drug: dian dao san
dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks

Outcome Measures

Primary Outcome Measures

  1. reduction of flushing, erythema, telangiectasia, papules, and pustules [6 weeks]

    quantified by Investigator Global Assessment, IGA. IGA is used in the study for assessing the severity of rosacea ranging from 0 (clean) to 4 (most severe).

  2. absence of adverse skin reaction to topical medicine [6 weeks]

    scored with Dyshidrotic Eczema Area and Severity Index (DASI index). The total score of the DASI results from the sum of severity grade score points of each of the four items (V = vesicles, E = erythema, S = desquamation, I = itch) multiplied by the affected area (A) score points: DASI = (pV + pE + pS + pI) × pA. The maximum possible score is 60. By the DASI, the dyshidrotic eczema is graded as: mild (0-15), moderate (16-30) and severe (31-60).

Secondary Outcome Measures

  1. improvement of life quality [6 weeks]

    Dermatology Quality of Life Index, DQoL is the questionnaire which designed to measure the health-related quality of life of adult patients suffering from a skin disease ranging from 0(no effect at all on patient's life) to 30(extremely large effect on patient's life).

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Willing to sign inform consent

  • Aged above 20 years old with rosacea

  • No treatment for rosacea within 2 weeks

Exclusion Criteria:
  • With malignant lesion in the rosacea lesion

  • Rosacea lesion with high risk of infection

  • Allergy to Chinese herbal medicine patch or ointment

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Keelung Chang Gung Memorial Hospital Keelung Taiwan

Sponsors and Collaborators

  • Chang Gung Memorial Hospital

Investigators

  • Principal Investigator: YUAN-CHIEH YEH, Doctor, Chang Gung Memorial Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier:
NCT05045469
Other Study ID Numbers:
  • 202101000A3
First Posted:
Sep 16, 2021
Last Update Posted:
Sep 22, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2021